Valneva SE (NASDAQ:VALN) Short Interest Update

Valneva SE (NASDAQ:VALN) saw a significant decrease in short interest in the month of December. As of December 15th, there was short interest totalling 24,300 shares, a decrease of 20.6% from the November 30th total of 30,600 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average trading volume of 30,000 shares, the days-to-cover ratio is presently 0.8 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright dropped their price objective on shares of Valneva from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Friday, October 11th.

Valneva Stock Down 0.2 %

Shares of VALN traded down $0.01 during trading hours on Monday, hitting $4.32. The company had a trading volume of 70,318 shares, compared to its average volume of 16,823. Valneva has a one year low of $3.62 and a one year high of $10.76. The company’s fifty day moving average price is $4.70 and its two-hundred day moving average price is $6.14. The company has a market capitalization of $351.05 million, a PE ratio of -33.23 and a beta of 1.98. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70.

Institutional Trading of Valneva

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC raised its holdings in shares of Valneva SE (NASDAQ:VALN) by 33.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 118,000 shares of the company’s stock after purchasing an additional 29,748 shares during the period. AlphaCentric Advisors LLC owned 0.15% of Valneva worth $717,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.